BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29321818)

  • 1. EWS-FLI-1 creates a cell surface microenvironment conducive to IGF signaling by inducing pappalysin-1.
    Jayabal P; Houghton PJ; Shiio Y
    Genes Cancer; 2017 Nov; 8(11-12):762-770. PubMed ID: 29321818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of FLI-1-EWS, a fusion gene reciprocal to EWS-FLI-1, in Ewing sarcoma.
    Elzi DJ; Song M; Houghton PJ; Chen Y; Shiio Y
    Genes Cancer; 2015 Nov; 6(11-12):452-61. PubMed ID: 26807198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
    Prieur A; Tirode F; Cohen P; Delattre O
    Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth.
    Johnson KM; Mahler NR; Saund RS; Theisen ER; Taslim C; Callender NW; Crow JC; Miller KR; Lessnick SL
    Proc Natl Acad Sci U S A; 2017 Sep; 114(37):9870-9875. PubMed ID: 28847958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic Analysis of the EWS-Fli-1 Interactome Reveals the Role of the Lysosome in EWS-Fli-1 Turnover.
    Elzi DJ; Song M; Hakala K; Weintraub ST; Shiio Y
    J Proteome Res; 2014 Aug; 13(8):3783-91. PubMed ID: 24999758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model.
    González I; Vicent S; de Alava E; Lecanda F
    J Mol Med (Berl); 2007 Sep; 85(9):1015-29. PubMed ID: 17453169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
    Castillero-Trejo Y; Eliazer S; Xiang L; Richardson JA; Ilaria RL
    Cancer Res; 2005 Oct; 65(19):8698-705. PubMed ID: 16204038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Epileptic Drug Targets Ewing Sarcoma.
    Kayarthodi S; Fujimura Y; Fang J; Morsalin S; Rao VN; Reddy ES
    J Pharm Sci Pharmacol; 2014 Jun; 1(2):87-100. PubMed ID: 25664332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
    Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
    PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.
    Johnson KM; Taslim C; Saund RS; Lessnick SL
    PLoS One; 2017; 12(11):e0186275. PubMed ID: 29091716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slit2 signaling stimulates Ewing sarcoma growth.
    Suvarna K; Jayabal P; Ma X; Shiio Y
    Genes Cancer; 2022; 13():88-99. PubMed ID: 36533189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma.
    Boone MA; Taslim C; Crow JC; Selich-Anderson J; Byrum AK; Showpnil IA; Sunkel BD; Wang M; Stanton BZ; Theisen ER; Lessnick SL
    Oncogene; 2021 Jul; 40(29):4759-4769. PubMed ID: 34145397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma.
    Chaturvedi A; Hoffman LM; Welm AL; Lessnick SL; Beckerle MC
    Genes Cancer; 2012 Feb; 3(2):102-16. PubMed ID: 23050043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
    Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
    Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
    Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
    Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.
    Heitzeneder S; Sotillo E; Shern JF; Sindiri S; Xu P; Jones R; Pollak M; Noer PR; Lorette J; Fazli L; Alag A; Meltzer P; Lau C; Conover CA; Oxvig C; Sorensen PH; Maris JM; Khan J; Mackall CL
    J Natl Cancer Inst; 2019 Sep; 111(9):970-982. PubMed ID: 30698726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.